Spare the rod and spoil the eye

British Journal of Ophthalmology

Volumn 89, Issue 6, 2005, Pages 764-769

  Arden, G B ^a   Sidman, R L ^b   Arap, W ^c   Schlingemann, R O ^d  

^a CITY UNIVERSITY   (United Kingdom)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; ANOXIA; CLINICAL TRIAL; DARK ADAPTATION; DIABETIC RETINOPATHY; DISEASE SEVERITY; HUMAN; HYPOXIA; ILLUMINATION; LASER COAGULATION; LIPID OXIDATION; NONHUMAN; OXYGEN SUPPLY; PATHOGENESIS; PATHOPHYSIOLOGY; PHOTORECEPTOR; PIGMENT EPITHELIUM; PREVALENCE; PRIORITY JOURNAL; RETINA DEGENERATION; RETINA MACULA AGE RELATED DEGENERATION; RETINA ROD; RETROLENTAL FIBROPLASIA; REVIEW; SIGNAL TRANSDUCTION; SUBRETINAL NEOVASCULARIZATION; TREATMENT INDICATION; VISION;

ANIMALS; CELL HYPOXIA; CYTOKINES; DARK ADAPTATION; DIABETIC RETINOPATHY; HUMANS; INFANT, NEWBORN; MACULAR DEGENERATION; RETINAL DISEASES; RETINAL NEOVASCULARIZATION; RETINOPATHY OF PREMATURITY; RODS (RETINA); SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 20344391160     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2004.062547     Document Type: Review

References (100)

1. Witmer AN, Vrensen GFJM, Van Noorden CF, et al. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003;22:1-29.
2. Pugh ENJ, Nikonov S, Lamb TD. Molecular mechanisms of vertebrate photoreceptor light adaptation. Curr Opin Neurobiol 1999;9:410-18.
3. Ebrey T, Koutalos Y. Vertebrate photoreceptors. Prog Ret Eye Res 2001;20:49-94.
4. Hurley JB. Commentary. Shedding light on adaptation. J Gen Physiol 2002;119:125-8.
5. Young, RW, Bok D. Participation of the retinal pigment epithelium in the rod outer segment renewal process. J Cell Biol 1969;42:392-403.
6. Kern TS, Engerman RL. Capillary lesions develop in retina rather than in cerebral cortex in diabetes and experimental galactosaemia. Arch Ophthalmol 1996;114:306-7.
7. Dowling JE. The retina: an approachable part of the brain. Cambridge, MA: Belknap Press of Harvard University Press, 1987:282.
8. Hagins WA, Ross PD, Tate RI, et al. Transduction heats of retinal rods. Tests of the role of cGMP by pyroelectric calorimetry. Proc Natl Acad Sci USA 1989;86:1224-8.
9. McFarland RA, Evans JN. Dark adaptation and reduced oxygen tension. Am J Physiol 1939;127:37-50.
10. Havelius U, Bergqvist D, Falke P, et al. Impaired dark adaptation in symptomatic carotid artery disease. Neurology 1997;49:1353-9.
11. Havelius U, Bergqvist D, Hindfelt B, et al. Improved dark adapation after carotid endarterectomy. Evidence of a long-term ischaemic penumbra. Neurology 1997;49:1360-4.
12. Havelius H, Berglund S, Falke P, et al. Impaired dark adaptation in polycythaemia. Improvement after treatment. Acta Ophthalmol Scand 2000;78:53-7.
13. Linsenmeier RA. The effect of light and darkness on oxygen distribution and consumption in the cat retina. J Gen Physiol 1986;88:521-42.
14. Braun RD, Linsenmeier RA. Oxygen consumption in the inner and outer retina of the cat. Invest Ophthal Vis Sci 1995;36:542-54.
15. Haugh LM, Scheldt IA, Griff ER, et al. Light evoked oxygen responses in the toad retina. Exp Eye Res 1995;61:73-81.
16. Arden GB. The absence of diabetic retinopathy in patients with retinitis pigmentosa: Implications for pathophysiology and possible treatment. Br J Ophthalmol 2001;85:366-70.
17. Harris A, Danis RP, Evans S, et al. Hyperoxia improves contrast sensitivity in early diabetic retinopathy. Br J Ophthalmol 1996;80:209-13.
18. Dean F, Dornhorst A, Arden GB. Partial reversal of protan and triton colour defects with inhaled oxygen in insulin dependent diabetic subjects. Br J Ophthalmol 1997;81:27-30.
19. Drasdo N, Chiti Z, Owens DR, et al. Effect of darkness on inner retinal hypoxia in diabetes. Lancet 2002;359:2251-3.
20. Linsenmeier RA, Braun RD, McRipley MA, et al. Retinal hypoxia in long term diabetic cats. Invest Ophthalmol Vis Sci 1998;39:1647-58.
21. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-20.
22. Mitzutani M, Kern TS, Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopothy. J Clin Invest 1996;97:2883-90.
23. Gardner TW, Antonetti DA, Barber AJ, et al. Diabetic retinopothy: more than meets the eye. Survey Ophthalmol, 2002;47(Suppl 2) S253-62.
24. Williamson JR, Chang K, Frangos M, et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993;42:801-13.
25. Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Current Topics in Microbiology and Immunology 1999;237:1-30.
26. Lu M, Kuroki M, Amano S, et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest 1998;101:1219-24.
27. Sone H, Kawakami Y, Okudo Y, et al. Ocular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes. Diabetologia 1997;40:726-30.
28. Murata T, Nakagawa K, Khalil A, et al. 1. The relation between the expression of VEGF and the breakdown of BRB in diabetic rat retinas. Lab Invest 1994;74:819-25.
29. Amin RH, Frank RN, Kennedy A, et al. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 1997;38:36-47.
30. Gilbert RE, Vranes D, Berka JL, et al. Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. Lab Invest 1998;78:1017-27.
31. Hammes HP, Lin J, Bretzel RG, et al. Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes 1998;47:401-6.
32. Joussen AM, Poulaki V, Qin W, et al. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initials early diabetic retinal leucocyte adhesion in vivo. Am J Pathol 2002;160:501-9.
33. Segawa Y, Shirao Y, Yamagishi S, et al. Upregulation of vascular endothelial growth factor mRNAs in spontaneously diabetic rats without ophthalmoscopic retinopathy. A possible participation of advanced glycation end products in the early phase of diabetic retinopathy. Ophthalmic Res 1998;30:333-9.
34. Hofman P, Van Blijswijk BC, Gaillard PJ, et al. Endothelial cell hypertrophy induced by vascular endothelial growth factor in the retina: new insights into the pathogenesis of capillary nonperfusion. Arch Ophthalmol 2001;119:861-6.
35. Quam T, Xu Q, Joussen AM, et al. VEGF-initiated blood retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 2001;42:2408-13.
36. Nomura M, Yamagishi S, Harada S, et al. Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes. J Biol Chem 1995;270:28316-24.
37. Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996;103:1820-8,
38. Hofman P, Blaauwgeers HG, Vrensen GFJM, et al. Role of VEGF-A in endothelial phenotypic shift in human diabetic retinopathy and in VEGF-A induced retinopathy in monkeys. Ophthalmic Res 2001;33:156-62.
39. Sharma NK, Gardiner TA, Archer DB. A morphologic and autoradiographic study of cell death and regeneration in the microvasculature of normal and diabetic rats. Am J Ophthalmol 1985;100:51-60.
40. Lahdenranta J, Pasqualini R, Schlingemann RO, et al. An anti-angiogenic state in mice and humans with retinal photoreceptor degeneration. Proc Natl Acad Sci USA 2001;98:10368-73.
41. Leu A to G mutation. Adv Exp Med Biol 1999;169:661-70.
42. Sue CM, Mitchell P, Crimmins DS, et al. Pigmentary retinopathy associated with the mitochondrial DNA 3243. Neurology 1997;49:1013-17.
43. Holmes-Walker DJ, Mitchell P, Boyages SC. Does mitochondrial genome mutation in subjects with maternally inherited diabetes and deafness decrease severity of diabetic retinopathy? Diabetic Med 1998;15:946-52.
44. Marsh S, Nakhoul FM, Skorecki K, et al. Hypoxic induction of vascular endothelial growth factor is markedly decreased in diabetic individuals who do not develop retinopathy. Diabetes Care 2000;23:1375-80.
45. Yu DY, Cringle SJ. Oxygen distribution and consumption within the retina in vascularised and avascular retinas and in animal models of retinal disease. Prog Retina Eye Res 2001;20:175-208.
46. Nguyen QD, Shah SM, van Anden E, et al. Supplemental oxygen improves diabetic macular edema: a pilot study. Invest Ophthalmol Vis Sci 2004;45:617-24.
47. Arden GB, Schlingeman RO. Oxygen and diabetic retinopathy. e-publication Invest Ophthalmol Vis Sci 5 Jan 2005 (comment on ref 46).
48. Kondo T, Vicent D, Suzuma K, et al. Knockout of insulin and IGF-1 receptors on vascular endothelial cells protects against retinal neovascularization. J Clin Invest 2003;111:1817-19.
49. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994;35:101-11.
50. Wesolowski E, Smith LE. Effect of light on oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994;35:112-19.
51. Reynolds JD, Hardy RJ, Kennedy KA, et al. Lack of efficiacy of light reduction in preventing retinopathy of prematurity. New Engl J Med 1998;338:1572-0.
52. Zack DJ, Dean M, Molday RS, et al. What can we learn about age-related macular degeneration from other retinal diseases? Mol Vis 1999;5:30.
53. Darzins P, Mitchell P, Heller RF. Sun exposure and age-related macular degeneration. An Australian case-control study. Ophthalmology 1997;104:770-6.
54. Cai J, Nelson KC, Wu M, et al. Oxidative damage and protection of the RPE. Prog Retin Eye Res 2000;19:205-21.
55. Beatty S, Koh H, Phil M, et al. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2000;45:115-34.
56. Zarbin MA. Age-related macular degeneration: review of pathogenesis. Eur J Ophthalmol 1998;8:199-206.
57. Green WR. Histopathology of age-related macular degeneration. Mol Vis 1999;5:27.
58. Lutty G, Grunwald J, Majji AB, et al. Changes in choriocapillaris and retinal pigment epithelium in age-related macular degeneration. Mol Vis, 1999;5:35.
59. Adler R, Curcio C, Hicks D, et al. Cell death in age-related macular degeneration. Mol Vis 1999;5:31.
60. Nguyen-Legros J, Hicks D. Renewal of photoreceptor outer segments and their phagocytosis by the retinal pigment epithelium. Int Rev Cytol 2000;196:245-313.
61. Marmorstein AD, Finnemann SC, Bonilha VL, et al. Morphogenesis of the retinal pigment epithelium: toward understanding retinal degenerative diseases. Ann NY Acad Sci 1998;857:1-12.
62. Hageman GS, Luthert PJ, Victor Chong NH, et al. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 2001;20:705-32.
63. Gu X, Meer SG, Miyagi M, et al. Carboxyethylpyrrole protein adducts and autoantibodies, biomarkers for age-related macular degeneration. J Biol Chem 2003;278:42027-35.
64. Reme CE, Hafezi F, Marti A, et al. Light damage to retina and retinal pigment epithelium. In: Marmor MF, Wolfensberger, eds. The retinal pigment epithelium. New York: OUP, 1998;Chapter 29:563-86.
65. Malek G, Li CM, Guidry C, et al. Apolipoprotein B in cholesterol- containing drusen and basal deposits of human eyes with age-related maculopathy. Am J Pathol 2003;162:413-25.
66. Spraul CW, Lang GE, Grossniklaus HE. Morphometric analysis of the choroid, Bruch's membrane, and retinal pigment epithelium in eyes with age-related macular degeneration. Invest Ophthalmol Vis Sci 1996;37:2724-35.
67. Ciulla TA, Harris A, Kagemann L, et al. Choroidal perfusion perturbations in non-neovascular age related mocular degeneration. Br J Ophthalmol 2002;86:209-13.
68. Jackson GR, Owsley C, Curcio CA. Photoreceptor degeneration and dysfunction in aging and age-related maculopathy. Ageing Res Rev 2002;1:381-96.
69. Holz FG, Gross-Jendroska M, Eckstein A, et al. Colour contrast sensitivity in patients with age-related Bruch's membrane changes. Ger J Ophthalmol 1995;4:336-41.
70. Mackenzie PJ, Chang TS, Scott IU, et al. Assessment of vision-related function in patients with age-related macular degeneration. Ophthalmology 2002;109:720-9.
71. Cheng AS, Vingrys AJ. Visual losses in early age-related maculopathy. Optom Vis Sci 1993;70:89-96.
72. Brown B, Adams AJ, Coletta NJ, et al. Dark adaptation in age-related maculopathy. Ophthalmic Physiol Opt 1986;6:81-4.
73. Eisner A, Fleming SA, Klein ML, et al. Sensitivities in older eyes with good acuity: eyes whose fellow eye has exudative AMD. Invest Ophthalmol Vis Sci 1987;28:1832-7.
74. Owsley C, Jackson GR, Cideciyan AV, et al. Psychophysical evidence for rod vulnerability in age-related macular degeneration. Invest Ophthalmol Vis Sci 2000;41:207-73.
75. Haimovici R, Owens SL, Fitzke FW, et al. Dark adaptation in age-related macular degeneration: relationship to the fellow eye. Graefes Arch Clin Exp Ophthalmol 2002;240:90-5.
76. Smith VC, Pokorny J, Diddie KR. Color matching and the Stiles-Crawford effect in observers with early age-related macular changes. J Opt Soc Am A 1988;5:2113-21.
77. Frennesson IC, Nilsson SE. Laser photocoagulation of soft drusen in early age-related maculopathy (ARM). The one-year results of a prospective, randomised trial. Eur J Ophthalmol 1996;6:307-14.
78. Arden GB, Wolf JE. Differential effects of light and alcohol on the electro-oculographic responses of patients with age-related macular disease. Invest Ophthalmol Vis Sci 2003;44:3226-32.
79. Arden GB, Wolf JE. Colour vision as a screening test for age-related maculopathy. Br J Ophthalmol 2004;88:1180-5.
80. Curcio CA. Photoreceptor topography in ageing and age-related maculopathy. Eye 2001;15:376-83.
81. Kent D, Vinores SA, Campochiaro PA. Macular oedema: the role of soluble mediators. Br J Ophthalmol 2000;84:542-5.
82. Holz FG, Sheraidah G, Pauleikhoff D, et al. Analysis of lipid deposits extracted from human macular and peripheral Bruch's membrane. Arch Ophthalmol 1994;112:402-6.
83. Ramrattan RS, van der Schaft TL, Mooy CM, et al. Morphometric analysis of Bruch's membrane, the choriocapillaris, and the choroid in aging. Invest Ophthalmol Vis Sci 1994;35:2857-64.
84. Blaauwgeers HG, Holtkamp GM, Rutten H, et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol 1999;155:421-8.
85. Spilsbury K, Garrert KL, Shen WY, et al. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol 2000;157:135-44.
86. Bo D'Amore PA. Mechanisms of retinal and choroidal neovascularization. Invest Ophthalmol Vis Sci 1994;35:3974-9.
87. Schlingemann RO. Role of growth factors and the wound healing response in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2004;242:91-101.
88. Abdelsalam A, Del Priore L, Zarbin MA. Drusen in age-related macular degeneration: pathogenesis, natural course, and laser photocoagulation induced regression. Surv Ophthalmol 1999;44:1-29.
89. Sarks SH, Arnold JJ, Sarks JP, et al. Prophylactic perifoveal laser treatment of soft drusen. Aust N Z J Ophthalmol 1996;24:15-26.
90. Little HL, Showman JM, Brown BW. A pilot randomized controlled study on the effect of laser photocoagulation of confluent soft macular drusen. Ophthalmology 1997;104:623-31.
91. Guymer RH, Gross-Jendroska M, Owens SL, et al. Laser treatment in subjects with high-risk clinical features of age-related macular degeneration. Posterior pole appearance and retinal function. Arch Ophthalmol 1997;115:595-603.
92. Ho AC, Maguire MG, Yoken J, et al. Laser-induced drusen reduction improves visual function at 1 year. Choroidal Neovascularization Prevention Trial Research Group. Ophthalmology 1999;106:1367-73.
93. Frennesson C, Nilsson SE. Prophylactic laser treatment in early age related maculopathy reduced the incidence of exudative complications. Br J Ophthalmol 1998;82:1169-74.
94. Weirzig PC. Photocoagulation of drusen-related macular degeneration. Trans Am Ophthalmol Soc 1994;92:299-306.
95. Holtz FG, Gross-Jendrowska M, Eckstein A, et al. Colour contrast sensitivity in patients with age-related Bruch's membrane changes. Ger J Ophthalmol 1985;4:336-41.
96. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age- related macular degeneration. Updated findings from two clinical trials. Arch Ophthalmol 1993;111:1200-9.
97. Voutilainen-Kaunisto RM, Terasvirta ME, Uusitupa MI, et al. Age-related macular degeneration in newly diagnosed type 2 diabetic patients and control subjects: a 10-year follow-up on evolution, risk factors, and prognostic significance. Diabetes Care 2000;23:1672-8.
98. Zylbermann R, Landau D, Rozenman Y, et al. Exudative age-related macular degeneration in patients with diabetic retinopathy and its relations to retinal laser photocoagulation. Eye 1997;11:872-5.
99. Deutman AF, Hoyng CB, Meulenduks CFM, et al. The Eyetech Anti-VEGF Study. Ophthalmic Res Suppl 2004 EVER abstract, 2162.
100. Leys A. Lucentis in the treatment of AMD. Ophthalmic Res Suppl. 2004 EVER abstract, 2163.